abstract |
A method of diagnosing whether a subject has pancreatic, prostate or stomach cancer, which comprises: measuring the level of at least one first miR-92-2 gene product in a sample of the subject's pancreas, prostate or stomach tissue, in that an alteration in the level of the first miR-92-2 gene product in the sample, in relation to the level of the first miR-92-2 gene product in a control sample, is indicative that the subject has cancer of pancreas, prostate or stomach. |